Actuate Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.3351 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 18.43M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Details
| Name | Actuate Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 12 |
| Founded | 2015 |
| Ipo Date | 2024-08-13 |
| Ceo | Daniel Schmitt |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 8.00 |
| Isin | US0050831009 |
| Cusip | 005083100 |
| Cik | 1652935 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Andrew P. Mazar Ph.D. | Co-Founder and Chief Operating Officer |
| Paul J. Lytle CPA | Chief Financial Officer |
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
Contact
| Address | 1751 River Run, Suite 400, Fort Worth, Texas 76107, United States |
| Phone | 817 887 8455 |
| Website | https://actuatetherapeutics.com |